Immunogenicity of a 23-valent pneumococcal polysaccharide vaccine in elderly residents of a long-term care facility

Brazilian Journal of Infectious Diseases

Volumn 11, Issue 3, 2007, Pages 322-326

  Valenzuela, M Teresa B ^a   Altuzarra, Rogelio H ^a   Trucco, Olivia A ^a   Villegas, Rodrigo R ^a   Inostroza, Jaime S ^b   Granata, Paulo S ^a   Fleiderman, José V ^a   Maggi, Leonardo C ^a  

^a UNIVERSIDAD DE LOS ANDES   (Chile)

^b UNIVERSIDAD DE LA FRONTERA   (Chile)

Author keywords

Antibodies; Elderly; Immunogenicity; Streptococcus pneumoniae; Vaccine

Indexed keywords

BACTERIUM ANTIBODY; PNEUMOCOCCUS VACCINE; TETANUS TOXOID;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; BACTERIAL IMMUNITY; CHILE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; ELDERLY CARE; FEMALE; HIGH RISK POPULATION; HUMAN; IMMUNOGENICITY; INFECTION RISK; INJECTION SITE PAIN; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; MALE; NURSING HOME PATIENT; RANDOMIZED CONTROLLED TRIAL; SEROTYPE; SINGLE DRUG DOSE; SKIN REDNESS; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; SYSTEMIC DISEASE; VACCINATION;

EID: 35448951390     PISSN: 14138670     EISSN: None     Source Type: Journal    
DOI: 10.1590/s1413-86702007000300005     Document Type: Article

References (23)

1. High K.P. Pneumonia in older adults New categories add complexity to diagnosis and care. Postgraduate Medicine 2005;118:18-28.
2. Fedson D., Anthony J., Scott G. The burden of pneumococcal disease among adults in developed and developing countries: what is and is not known. Vaccine 1999, S11-S8.
3. Kalin M., Örtqvist A., Almeda M., et al. Prospective study of prognosis factors in community-acquired bacteremic pneumococcal disease in 5 countries. J Infect Dis 2000;182:840-7.
4. Obaro S.K., Monteil M.A., Henderson D.C. The pneumoccocal problem. BMJ 1998;312:1521-5.
5. Muder R.R., Aghababian R.V., Loeb M.B., et al. Nursing home-acquired pneumonia: an emergency department treatment algorithm. Curr Med Res Opin 2004;20:1309-20.
6. Loeb M. Epidemiology of community- and nursing home-acquired pneumonia in older adults.Expert Rev Anti Infect Ther 2005;Apr;3(2):263-70.
7. Jackson M.L., Neuzil K.M., Thompson W.W., et al. The burden of community-acquired pneumonia in seniors: results of a population-based study. Clin Infect Dis 2004;39:1642-50.
8. Inostroza J., Vinet A., Retamal P., et al. Influence of patient age on Streptococcus pneumoniae serotypes causing invasive disease. Clin Diagn Lab Immunol 2001:8(3):556-9.
9. MINSAL. División de Salud de las personas. Programa Especial de Control de las Enfermedades Respiratorias del Adulto en Chile, Matzo, 2001.
10. Fine M.J., Smith M.A., Carson C.A., et al. Prognosis and outcomes of patients with community-adquired pneumonia. JAMA 1996;275:134-41.
11. Centers for Disease Control and Prevention. Influenza and pneumococcal vaccination levels among adults aged > 65 years. United States. MMWR Morbid Mortal Wkly Rep 1998;47:797-802.
12. Soininen A., Karpala M., Wahlman L., et al. Specifities and opsonophagocytic activities of antibodies to pneumococal capsular polysaccharides in sera of unimmunized young children. Clinical and Diagnostic Laboratory Immunology 2002;5:1032-8.
13. Laurence E.M., Edwards K.M., Schiffmann G., et al. Pneumococcal vaccine in normal children. An J Dis Child 1983;137:846-50.
14. Altuzarra R., Valenzuela M.T., Trucco O., et al. Portación nasal de Streptococcus pneumoniae en Adulto mayor y su respuesta frente a la vacunación antineumocócic. (accepted for publication).
15. Hormazabal J.C., Heitmann I., Rojo P., et al. Serotipos de S.pneumoniae asociados a patología invasiva del adulto. Instituto de Salud Pública, Laboratorio de Referencia cocáceas Gram positivas. Programa Microbiología-Micología ICBM, Facultad de Medicina, Universidad de Chile. Presentado en el XIX Congreso Chileno de Infectología. Nov. 2002.
16. a):69S-76S.
17. Nichol C.L. The additive benefits of influenza and pneumococcal vaccinations during influenza seasons among elderly persons with chronic lung disease. Vaccine 1999;17:S91-S3.
18. Sims R.V,, Steinmann W.C., McConville J.H., et al. The clinical effectiveness of pneumococcal vaccine in the elderly. Ann Inter Med 1988;108:653-7.
19. Shapiro E.D., Berg A.T., Austrian R., et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991; 325:1453-60.
20. Buttler J.C., Breiman R.F., Campbell J.F., et al. Pneumococcal polysaccharide vaccine efficacy: An evaluation of current recommendations. JAMA 1993;270:1826-31.
21. Sisk J.E., Moskowitz A.J., Whang W., et al. Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people. JAMA 1997;278:1333.
22. Ament A., Baltussen R., Duru G., et al. Cost-effectiveness of pneumococcal vaccination of older people: study in 5 western european countries. Cl Inf Dis 2000;31:444-50.
23. Centers for Disease Control. Pneumococcal polysaccharide vaccine usage, United States. MMWR 1984;33:273-86.